Current Edition

antibody drug conjugates

ASH: Roche’s Polivy set to unlock $2B market in newly diagnosed lymphoma with practice-changing data

The guessing is over. Roche has detailed new Polivy data that could change nearly two decades of treatment standards in newly diagnosed lymphoma—while opening up …

Continue Reading →

Roche’s Polivy to hit $2.4B as doctors expect ‘significant switching’ in newly diagnosed lymphoma: analyst

Roche Pharmaceuticals CEO Bill Anderson recently pegged lymphoma drug Polivy’s potential expansion into newly diagnosed patients as a multibillion-dollar opportunity. Now, at least one analyst …

Continue Reading →